Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)

Volume: 26, Issue: 7, Pages: 803 - 811
Published: Jun 9, 2017
Abstract
Introduction: Acute myelogenous leukemia (AML) is a heterogeneous group of malignancies driven by genetic mutations and deregulated epigenetic control. Relapse/refractory disease remains frequent in younger patients and even more so in older patients, including treatment with epigenetic drugs in this age group, mainly with hypomethylating agents. New treatment strategies are urgently needed. The recent discovery that epigenetic readers of the...
Paper Details
Title
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)
Published Date
Jun 9, 2017
Volume
26
Issue
7
Pages
803 - 811
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.